Il Pharmacovigilance Risk Assessment Committee (PRAC) dellEMA ha esaminato il segnale nella sessione di giugno 2025 e ha concluso la propria valutazione nella sessione di novembre 2025
Dose adjustments are generally not required for patients with renal impairment, as semaglutide is not primarily eliminated by the kidneys
Now, lets leave this nostalgia of this inclusive paradise and fast forward to today
Observational studies supported these findings, indicating fewer alcohol-related healthcare events among GLP-1 RA users compared to non-users or those on alternative treatments
GSH deficiency results in the activation of von Willebrand Factor (Ibrahim et al., 2004) and in the accumulation of ROS, which affect clotting and platelet activation, impair endothelial function, and predispose to the risk of thrombotic events (Violi et al., 2017): notably, hypercoagulation is a prominent life-threatening complication in COVID-19 patients (Giardini et al., 2020)